Top

Published in:

01-08-2016 | Original Communication

Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population

Authors: Xingyang Yi, Chun Wang, Ping Liu, Cheng Fu, Jing Lin, Yiming Chen

Published in: Journal of Neurology | Issue 8/2016

Abstract

To evaluate the prevalence and risk factors of antiplatelet drug resistance and its association with early neurological deterioration (END) and recurrent ischemic stroke (RIS) in patients with acute minor stroke. Antiplatelet drug resistance was assessed by platelet aggregation assay in 426 patients with minor stroke who were receiving combined treatment of aspirin and clopidogrel. All patients were followed up for 90 days. The primary endpoint of the study was END within 10 days after admission. The secondary endpoints included RIS, myocardial infarction and death during 90 days of treatment. The safety endpoints were intracerebral or extracranial hemorrhagic events. Cox proportional hazard regression analysis was performed to determine the risk factors for the primary endpoint and secondary endpoints. Among the 426 patients, 24.4 % exhibited aspirin resistance, 35.9 % exhibited clopidogrel resistance, and 19.2 % displayed concomitant aspirin and clopidogrel resistance. In multivariate analysis, diabetes mellitus and high level of low density lipoprotein-cholesterol were independent risk factors for aspirin resistance, while diabetes mellitus was the only independent risk factor for clopidogrel resistance. END was observed in 93 (21.8 %) patients. Diabetes mellitus, high fasting blood glucose level, and concomitant aspirin and clopidogrel resistance were independent risk factors for END. RIS was observed in 40 (9.4 %) patients. Diabetes mellitus, hypertension, and concomitant aspirin and clopidogrel resistance were independent risk factors for RIS. Antiplatelet drug resistance is common in acute minor ischemic stroke patients and is associated with END and RIS after acute minor ischemic stroke in the Chinese population.

Clinical Trial Registration Information: http://www.chictr.org/. Unique Identifier: ChiCTR-OCH-14004724.

Zhao D, Liu J, Wang W, Zeng Z, Cheng J, Liu J et al (2008) Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke 39:1668–1674. doi:10.1161/STROKEAHA.107.502807 CrossRefPubMed

Wang YL, Wu D, Liao X, Zhang W, Zhao X, Wang YJ (2007) Burden of stroke in China. Int J Stroke 2:211–213. doi:10.1111/j.1747-4949.2007.00142.x CrossRefPubMed

Smith EE, Fonarow GC, Reeves MJ, Cox M, Olson DM, Hernandez AF et al (2011) Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 42:3110–3115. doi:10.1161/STROKEAHA.111.613208 CrossRefPubMed

Nedeltchev K, Schwegler B, Haefeli T, Brekenfeld C, Gralla J, Fischer U et al (2007) Outcome of stroke with mild or rapidly improving symptoms. Stroke 38:2531–2535. doi:10.1161/STROKEAHA.107.482554 CrossRefPubMed

Alawneh JA, Moustafa RR, Baron JC (2009) Hemodynamic factors and perfusion abnormalities in early neurological deterioration. Stroke 40:e443–e450. doi:10.1161/STROKEAHA.108.532465 CrossRefPubMed

Yi X, Lin J, Wang C, Zhang B, Chi W (2014) A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. J Stroke Cerebrovasc Dis 23:1975–1981. doi:10.1016/j.jstrokecerebrovasdis.2014.01.022 CrossRefPubMed

Lovett JK, Coull AJ, Rothwell PM (2004) Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62:569–573CrossRefPubMed

Ois A, Gomis M, Rodriguez-Campello A, Cuadrado-Godia E, Jimenez-Conde J, Pont-Sunyer C et al (2008) Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke. Stroke 39:1717–1721. doi:10.1161/STROKEAHA.107.505438 CrossRefPubMed

Maas MB, Lev MH, Ay H, Singhal AB, Greer DM, Smith WS et al (2009) Collateral vessels on CT angiography predict outcome in acute ischemic stroke. Stroke 40:3001–3005. doi:10.1161/STROKEAHA.109.552513 CrossRefPubMedPubMedCentral

10.

Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C et al (2013) Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369:11–19. doi:10.1056/NEJMoa1215340 CrossRefPubMed

11.

Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD et al (2014) Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45:2160–2236. doi:10.1161/STR.0000000000000024 CrossRefPubMed

12.

CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) Lancet 349:1641–1649

13.

The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group (1997) Lancet 349:1569–1581

14.

Sandercock PA, Counsell C, Gubitz GJ, Tseng MC (2008) Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev CD000029. doi:10.1002/14651858.CD000029.pub2

15.

Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS et al (2000) Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 31:1240–1249CrossRefPubMed

16.

Committee CS (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329–1339CrossRef

17.

Makkar RR, Eigler NL, Kaul S, Frimerman A, Nakamura M, Shah PK et al (1998) Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 19:1538–1546CrossRefPubMed

18.

Yi X, Zhou Q, Lin J, Chi L (2013) Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. Int J Stroke 8:535–539. doi:10.1111/j.1747-4949.2012.00929.x CrossRefPubMed

19.

Yin T, Miyata T (2011) Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res 128:307–316. doi:10.1016/j.thromres.2011.04.010 CrossRefPubMed

20.

Patrono C (2014) Role of clinical pharmacology in the development of antiplatelet drugs. Clin Ther 36:2096–2111. doi:10.1016/j.clinthera.2014.10.012 CrossRefPubMed

21.

Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R et al (2010) Working group on high on-treatment platelet reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933. doi:10.1016/j.jacc.2010.04.047 CrossRefPubMed

22.

Jia DM, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ et al (2013) CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke 44:1717–1719. doi:10.1161/STROKEAHA.113.000823 CrossRefPubMed

23.

Yi X, Lin J, Zhou Q, Wu L, Cheng W, Wang C (2016) Clopidogrel resistance increases rate of recurrent stroke and other vascular events in chinese population. J Stroke Cerebrovasc Dis 25:1222–1228. doi:10.1016/j.jstrokecerebrovasdis.2016.02.013 CrossRefPubMed

24.

Schwammenthal Y, Tsabari R, Shenkman B, Schwartz R, Matetzky S, Lubetsky A et al (2008) Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis 25:355–361. doi:10.1159/000118382 CrossRefPubMed

25.

Han SW, Kim SH, Lee JY, Chu CK, Yang JH, Shin HY et al (2007) A new subtype classification of ischemic stroke based on treatment and etiologic mechanism. Eur Neurol 57:96–102. doi:10.1159/000098059 CrossRefPubMed

26.

Yi X, Zhou Q, Lin J, Chi L, Han Z (2013) Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C. J Atheroscler Thromb 20:65–72CrossRefPubMed

27.

Uzun F, Biyik I, Akturk IF, Erturk M, Yalcin AA, Surgit O et al (2015) Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postepy Kardiol Interwencyjnej 11:19–25. doi:10.5114/pwki.2015.49180 PubMedPubMedCentral

28.

Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908–2913. doi:10.1161/01.CIR.0000072771.11429.83 CrossRefPubMed

29.

Wang Q, Chen C, Chen XY, Han JH, Soo Y, Leung TW et al (2012) Low-molecular-weight heparin and early neurologic deterioration in acute stroke caused by large artery occlusive disease. Arch Neurol 69:1454–1460. doi:10.1001/archneurol.2012.1633 CrossRefPubMed

30.

Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E, Diener HC et al (2005) Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol 62:393–397. doi:10.1001/archneur.62.3.393 CrossRefPubMed

31.

Yi X, Chi W, Wang C, Zhang B, Lin J (2015) Low-molecular-weight heparin or dual antiplatelet therapy is more effective than aspirin alone in preventing early neurological deterioration and improving the 6-month outcome in ischemic stroke patients. J Clin Neurol 11:57–65. doi:10.3988/jcn.2015.11.1.57 CrossRefPubMedPubMedCentral

32.

Smock KJ, Saunders PJ, Rodgers GM, Johari V (2011) Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. Am J Hematol 86:1032–1034. doi:10.1002/ajh.22112 CrossRefPubMed

33.

Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H (2003) Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250:63–66. doi:10.1007/s00415-003-0954-y CrossRefPubMed

34.

Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28:1702–1708. doi:10.1093/eurheartj/ehm226 CrossRefPubMed

35.

Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L et al (2010) Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis 103:39–45. doi:10.1016/j.acvd.2009.11.004 CrossRefPubMed

36.

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363–375. doi:10.1056/NEJMoa0808227 CrossRefPubMed

37.

Bugnicourt JM, Roussel B, Garcia PY, Canaple S, Lamy C, Godefroy O (2011) Aspirin non-responder status and early neurological deterioration: a prospective study. Clin Neurol Neurosurg 113:196–201. doi:10.1016/j.clineuro.2010.11.004 CrossRefPubMed

38.

Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 8:1227–1234. doi:10.1038/nm1102-1227 CrossRefPubMed

39.

Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F et al (2002) Course of platelet activation markers after ischemic stroke. Stroke 33:2570–2574CrossRefPubMed

40.

Marcus AJ, Safier LB, Broekman MJ, Islam N, Fliessbach JH, Hajjar KA et al (1995) Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Thromb Haemost 74:213–217PubMed

41.

Fateh-Moghadam S, Li Z, Ersel S, Reuter T, Htun P, Plockinger U et al (2005) Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol 25:1299–1303CrossRefPubMed

42.

Serena J, Rodriguez-Yanez M, Castellanos M (2006) Deterioration in acute ischemic stroke as the target for neuroprotection. Cerebrovasc Dis 21(Suppl. 2):40–48

43.

Zhang X, Sun Z, Ding C, Tang Y, Jiang X, Xie Y et al (2016) Metabolic syndrome augments the risk of early neurological deterioration in acute ischemic stroke patients independent of inflammatory mediators: a hospital-based prospective study. Oxid Med Cell Longev 2016:8346301. doi:10.1155/2016/8346301 PubMedPubMedCentral

44.

Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B et al (2004) Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 113:101–113. doi:10.1016/j.thromres.2003.12.016 CrossRefPubMed

45.

Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ (2010) Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 7:251–259. doi:10.1177/1479164110383994 CrossRefPubMed

46.

Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM et al (2000) Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283:221–228CrossRefPubMed

47.

Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA et al (2008) Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 52:1968–1977. doi:10.1016/j.jacc.2008.07.068 CrossRefPubMed

48.

Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109. doi:10.1056/NEJMoa1209979 CrossRefPubMed

49.

Depta JP, Fowler J, Novak E, Katzan I, Bakdash S, Kottke-Marchant K et al (2012) Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. Stroke 43:2376–2381. doi:10.1161/STROKEAHA CrossRefPubMed

50.

Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233–1243. doi:10.1016/S0140-6736(10)61088-4 CrossRefPubMed

51.

Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ et al (1993) Aspirin response and failure in cerebral infarction. Stroke 24:345–350CrossRefPubMed

Title: Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population
Authors: Xingyang Yi
Chun Wang
Ping Liu
Cheng Fu
Jing Lin
Yiming Chen
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 8/2016
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-016-8181-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2016

Event-related EEG power modulations and phase connectivity indicate the focus of attention in an auditory own name paradigm

Alterations of functional and structural connectivity of freezing of gait in Parkinson’s disease

Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors

A painted staircase illusion to alleviate freezing of gait in Parkinson’s disease

Idiopathic rapid eye movement sleep behaviour disorder: a potential gateway to the development of disease-modifying treatments in neurodegenerative disorders

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society